Longitudinal SARS-CoV-2 mRNA vaccine-induced humoral immune responses in cancer patients

• Published in: Cancer research (Chicago, Ill.) Vol. 81; no. 24; pp. 6273 - 6280
• Main Authors: Figueiredo, Jane C., Merin, Noah M., Hamid, Omid, Choi, So Yung, Lemos, Tucker, Cozen, Wendy, Nguyen, Nathalie, Finster, Laurel J., Foley, Joslyn, Darrah, Justin, Gong, Jun, Paquette, Ronald, Mita, Alain C., Vescio, Robert, Mehmi, Inderjit, Basho, Reva, Tourtellotte, Warren G., Huynh, Carissa A., Melmed, Gil Y., Braun, Jonathan, McGovern, Dermot P.B., Mengesha, Emebet, Botwin, Greg, Prostko, John C., Frias, Edwin C, Stewart, James L., Joung, Sandy, Van Eyk, Jennifer, Ebinger, Joseph E., Cheng, Susan, Sobhani, Kimia, Reckamp, Karen L., Merchant, Akil
• Format: Journal Article
• Language: English
• Published: 10.11.2021

Longitudinal studies of SARS-CoV-2 vaccine-induced immune responses in cancer patients are needed to optimize clinical care. In a prospective cohort study of 366 (291 vaccinated) patients, we measured antibody levels [anti-spike (IgG-(S-RBD)) and anti-nucleocapsid immunoglobulin] at three timepoints...